The invention relates to novel inhibitors of the serine protease furin and to related furin-like proprotein convertases according to claim 1, and to methods of synthesis thereof and to use for production of medicaments for treatment of furin-dependent viral and bacterial infection diseases, and other disorders involving furin, such as cystic fibrosis, cancer, osteoarthritis, hypertension, and neurodegenerative disorders.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07D 211/26 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'azote
C07D 211/32 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre liés par des liaisons doubles ou par deux atomes d'oxygène ou de soufre, liés au même atome de carbone par des liaisons simples par des atomes d'oxygène
C07D 211/34 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 295/135 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants séparés par des carbocycles ou par des chaînes carbonées interrompues par des carbocycles
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
2.
ATP PRODUCTION FROM ELECTRICITY WITH A NEW-TO-NATURE ELECTROBIOLOGICAL MODULE
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Allemagne)
PHILIPPS-UNIVERSITÄT MARBURG (Allemagne)
Inventeur(s)
Erb, Tobias Jürgen
Luo, Shanshan
Heider, Johann
Abrégé
The present invention relates to a method and system for producing adenosine triphosphate (ATP) through an acid/aldehyde-ATP (AAA) cycle in an electrochemical cell.
The invention relates to an antisense molecule binding to the mRNA of the protein PLAC8 for use as a medicament, for example for the treatment of cancer, in particular pancreatic ductal adenocarcinoma. Furthermore, the use of such antisense molecules and a method for treating of cancer as well as a kit containing the antisense molecules are described.
A composition for the transport of a dissolved active agent into hair follicles is provided that includes an active agent dissolved in a topical dispersion medium, and submicron particles. In one aspect, a pharmaceutical composition is provided for use in transporting a dissolved pharmacologically active therapeutical and/or prophylactic agent into hair follicles including a pharmacologically active therapeutic and/or prophylactic agent dissolved in a topical dispersion medium, and submicron particles. In embodiments, the active agent is not chemically coupled to the submicron particles. In a further aspect, the composition is a cosmetic composition including a cosmetically active agent, and the cosmetic composition can be used in a cosmetic method, in which the cosmetic composition is applied to an area of skin with hair follicles.
The present invention relates to a method of determining complement activity, wherein said method comprises determining classical complement pathway activity, determining alternative complement pathway activity, and/or determining lectin complement pathway activity. The present invention further relates to a liposome collection for determining complement activity. Furthermore, the present invention relates to a kit for determining complement activity. The present invention also relates to a liposome collection or kit for use in a method of diagnosing, monitoring, or treating a complement associated disorder.
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
6.
BIODEGRADABLE PARTICLES FOR DRUG- OR GENE DELIVERY
Biodegradable particle comprising at least one cationic polymeric compound, the cationic polymeric compound being independently selected from the list comprising PEI, PLL, PLA and at least one drug or at least one genetic material, the genetic material being independently selected from the list comprising genes, siRNA, antisense oligonucleotides, DNA-sequences, RNA-sequences, long non- coding RNA, whereat the ratio of the sum of the negative charges of the phosphate groups in the genetic material or the sum of the negative charges of the at least one drug is equivalent to the sum of the positive charges in the at least one cationic polymer material.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
7.
NOVEL DESMOGLEIN 3 (DSG3)-EC5-SPECIFIC MONOCLONAL ANTIBODY DESIGNATED AS 2G4
Disclosed is a monoclonal IgG antibody designated as 2G4 which - is specific for the membrane-proximal extracellular region EC5 of Desmoglein-3 designated as human Dsg3-EC5 (aa451-566) - shows no cross-reaction with mouse Dsg3 or human Dsg1 - is capable of inhibiting the homophilic Dsg3-trans-interaction - induces cellular Dsg3 redistribution by activation of the p38MAPK signal transduction pathway and - exhibits pathogenic Ca2+-independent binding to human Dsg3. The B-cell hybridoma producing said novel antibody 2G4 has been deposited at DSMZ Braunschweig on January 11, 2022 under accession number DSM ACC3371. The novel antibody 2G4 can be used as an in vitro diagnostic for positive control of pemphigus vulgaris and as for analyzing the molecular and cellular mechanisms involved in pemphigus vulgaris. The invention further provides the monoclonal antibody 2G4 for use as a diagnostic for in vivo analyzing the molecular and/or cellular mechanisms involved in pemphigus vulgaris.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
8.
ANTIBACTERIAL PROPERTIES OF POLYPEPTIDES WITH NLPC/P60 DOMAINS
The invention relates to a polypeptide (e.g. comprised in a composition or medical device) for use as a medicament, the polypeptide, such as LytF, comprising a NlpC/P60 domain but no CHAP domain of LysK. The composition may further be used as an anti-infectiva such as an antibiotic in particular to treat gram-positive bacterial infections and/or disorder or disorders of the skin (e.g. formulated for epicutaneous administration). The invention further relates to a polynucleotide encoding the polypeptide described herein e.g. comprised in a vector or a host cell such as a bacterial cell. The polypeptide described herein may further be used in a disinfection solution, in packaging material and/or in biotechnological processes.
The invention relates to a method for detecting antibodies against leishmania in a biological sample. The invention also relates to a test for carrying out the method, the production of the test antigen and the test antigen with SEQ ID NO. 8.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/531 - Production de matériaux de tests immunochimiques
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
10.
ANTISENSE THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS
Disclosed herein are embodiments of a compound useful for treating or preventing SARS-Cov-2 infections. Also disclosed is a method for administering the compound to a subject, particularly a human subject, to treat or prevent a SARS-CoV-2 infection in the subject. The compound may comprise an oligomer comprising a nucleic acid base sequence that is antisense to a gene, pre-mRNA or mRNA in the subject, such as a gene, pre-mRNA or mRNA of transmembrane serine protease 2 (TMPRSS2). The compound also may comprise a peptide sequence. In some embodiments, the compound is a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).
The present application relates to a composition for increasing the solubility of an active substance, comprising crushed shell material, on or in which the active substance is sorbed. Furthermore, a method for producing the composition as well as its use are described
The invention provides new cyanine dyes for staining living cells, providing fluorescence emission in red, green and yellow, thus allowing “multichannel” staining. The dyes are binding to nucleic acids and allow the observation of the stained cells, for the staining does not negatively interfere with the viability of the stained cells. The inventive dyes thus can advantageously be used for pathogen-host investigations or any other type of investigation of cell-cell-interactions, for the natural behavior of the stained cells (microorganisms, pathogens etc.) can easily be observed.
C09B 23/02 - Colorants méthiniques ou polyméthiniques, p. ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre impair de groupes CH
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
The invention relates to a composition for the transport of a dissolved active agent into hair follicles, comprising an active agent dissolved in a topical dispersion medium, and submicron particles. In one aspect, the invention relates to a pharmaceutical composition for use in transporting a dissolved pharmacologically active therapeutical and/or prophylactic agent into hair follicles comprising a pharmacologically active therapeutic and/or prophylactic agent dissolved in a topical dispersion medium, and submicron particles. In embodiments, the active agent is not chemically coupled to the submicron particles. In a further aspect, the composition is a cosmetic composition comprising a cosmetically active agent, and the cosmetic composition can be used in a cosmetic method, wherein the cosmetic composition is applied to an area of skin with hair follicles.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 8/02 - Cosmétiques ou préparations similaires pour la toilette caractérisés par une forme physique particulière
A61K 8/35 - Cétones, p. ex. quinones, benzophénone
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
A61Q 7/00 - Préparations pour modifier la pousse des cheveux ou des poils
A61Q 19/00 - Préparations pour les soins de la peau
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
14.
SHORT-CHAIN FATTY ACID PENTANOATE AS ENHANCER FOR CELLULAR THERAPY AND ANTI-TUMOR THERAPY
The invention involves improving the cultivation of T cells by incubating them with short-chain fatty acid (SCFA) pentanoate after isolation from peripheral blood. The effect is that the cells are activated and the production of effector molecules is increased. This increases the chances of success of tumor therapy. This is illustrated by T-cells from mice that are transferred to mice with subcutaneous pancreatic tumors after the procedure. This type of cell treatment can be transferred to humans and the improved treatment of pancreatic cancer. We show in detail that the short-chain fatty acid (SCFA) pentanoate enhances the function of CD8+ cytotoxic T lymphocytes (CTLs). We show that Pentanoate promotes the core molecular signature of murine CD8+ CTLs. Pentanoate enhances anti-tumor activity of antigen-specific CTLs. Bacterial-derived SCFAs exhibit specific HDAC class I inhibitory activity. Pentanoate-producing bacteria enhance CD8+ T cell-mediated anti-tumor immune responses.
Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses, Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
C07D 307/93 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle condensés en ortho ou en péri avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle autre qu'un cycle à six chaînons
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN e.V. (Allemagne)
Philipps-Universität Marburg (Allemagne)
Inventeur(s)
Worzfeld, Thomas
Offermanns, Stefan
Abrégé
The present invention relates to a composition comprising an inhibitor of plexin-B1 and an inhibitor of plexin-B2, wherein the inhibitor of plexin-B1 and/or the inhibitor of plexin-B2 is/are preferably selected from (i) an inhibitor of the nucleic acid molecule encoding plexin-B1 and/or plexin-B2 selected from a small molecule, an aptamer, a siRNA, a shRNA, a miRNA, a morpholino, a ribozyme, an antisense nucleic acid molecule, a CRISPR-Cas9-based construct, a CRISPR-Cpf1-based construct, a meganuclease, a zinc finger nuclease, and a transcription activator-like (TAL) effector (TALE) nuclease, and/or (ii) an inhibitor of the plexin-B1 and/or plexin-B2 protein selected from a small molecule, an antibody or antibody mimetic, an aptamer, wherein the antibody mimetic is preferably selected from affibodies, adnectins, anticalins, DARPins, avimers, nanofitins, affilins, Kunitz domain peptides and Fynomers®.
Provided is a process which allows uranium and molybdenum fluorides to be efficiently separated, said process comprising a step of providing a mixture containing MoF6 and UF6; a step of reducing the UF6 to UF5 in the gas phase or in a liquid phase; and a step of separating the UF5 and the MoF6 or a conversion product thereof which may be obtained by further converting the molybdenum fluoride to another molybdenum compound. In a further aspect, a process for the fluorination of metals or semimetals is provided.
B01J 3/00 - Procédés utilisant une pression supérieure ou inférieure à la pression atmosphérique pour obtenir des modifications chimiques ou physiques de la matièreAppareils à cet effet
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
G21G 4/04 - Sources radioactives autres que les sources de neutrons
18.
NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS
The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof. The present invention also relates to the antibodies or antigen-binding fragments thereof, the pharmaceutical composition, and the kit, for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.
The present invention relates to antibodies or binding fragments thereof against SARS-related coronavirus, a pharmaceutical composition comprising such antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.
The present invention relates to antibodies or binding fragments thereof against SARS-related coronavirus, a pharmaceutical composition comprising such antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.
Disclosed herein are embodiments of a compound useful for treating or preventing SARS-Cov-2 infections. Also disclosed is a method for administering the compound to a subject, particularly a human subject, to treat or prevent a SARS-CoV-2 infection in the subject. The compound may comprise an oligomer comprising a nucleic acid base sequence that is antisense to a gene, pre-mRNA or mRNA in the subject, such as a gene, pre-mRNA or mRNA of transmembrane serine protease 2 (TMPRSS2). The compound also may comprise a peptide sequence. In some embodiments, the compound is a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 31/14 - Antiviraux pour le traitement des virus ARN
22.
TASK-1 INHIBITORS FOR TREATMENT OF ATRIAL ARRHYTHMIAS
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
wherein R1 is ethyl, —H, or methyl and R2 is a side chain having a structure as shown in formula (II)
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
wherein R1 is ethyl, —H, or methyl and R2 is a side chain having a structure as shown in formula (II)
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
wherein R1 is ethyl, —H, or methyl and R2 is a side chain having a structure as shown in formula (II)
wherein X1 is C═O, CH2, C═S, C—OH, C—NH2, or C—NO2, X2 to X4 are independently selected from CH2, C═O, C═S, C—OH, and C—NH2, or R2 is —NH2, for use in treating and/or preventing of atrial arrhythmia in a subject. The present invention further relates to pharmaceutical compositions and kit related to said compound.
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses (e.g., severe acute respiratory syndrome coronavirus [SARS-CoV], severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2, the virus and its mutant forms that cause COVID-19], Middle East respiratory syndrome coronavirus [MERS-CoV]), Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The invention involves improving the cultivation of T cells by incubating them with short-chain fatty acid (SCFA) pentanoate after isolation from peripheral blood. The effect is that the cells are activated and the production of effector molecules is increased. This increases the chances of success of tumor therapy. This is5 illustrated by T-cells from mice that are transferred to mice with subcutaneous pancreatic tumors after the procedure. This type of cell treatment can be transferred to humans and the improved treatment of pancreatic cancer. We show in detail that the short-chain fatty acid (SCFA) pentanoate enhances the function of CD8+ cytotoxic T lymphocytes (CTLs). We show that Pentanoate promotes the core molecular signature of murine CD8+ CTLs. Pentanoate enhances anti-tumor activity of antigen-specific CTLs. Bacterial- derived SCFAs exhibit specific HDAC class I inhibitory activity. Pentanoate- producing bacteria enhance CD8+ T cell-mediated anti-tumor immune responses.
The invention involves improving the cultivation of T cells by incubating them with short-chain fatty acid (SCFA) pentanoate after isolation from peripheral blood. The effect is that the cells are activated and the production of effector molecules is increased. This increases the chances of success of tumor therapy. This is5 illustrated by T-cells from mice that are transferred to mice with subcutaneous pancreatic tumors after the procedure. This type of cell treatment can be transferred to humans and the improved treatment of pancreatic cancer. We show in detail that the short-chain fatty acid (SCFA) pentanoate enhances the function of CD8+ cytotoxic T lymphocytes (CTLs). We show that Pentanoate promotes the core molecular signature of murine CD8+ CTLs. Pentanoate enhances anti-tumor activity of antigen-specific CTLs. Bacterial- derived SCFAs exhibit specific HDAC class I inhibitory activity. Pentanoate- producing bacteria enhance CD8+ T cell-mediated anti-tumor immune responses.
The invention comprises Metal complexes or semi-metal complexes of Phosphazenylphosphines, their manufacturing and their usage for catalyzing chemical reactions.
C08F 4/44 - MétauxHydrures métalliquesComposés organiques de métalLeur utilisation comme précurseurs de catalyseurs choisis parmi les métaux légers, le zinc, le cadmium, le mercure, le cuivre, l'argent, l'or, le bore, le gallium, l'indium, le thallium, les terres rares ou les actinides
C08F 4/60 - MétauxHydrures métalliquesComposés organiques de métalLeur utilisation comme précurseurs de catalyseurs choisis parmi les métaux légers, le zinc, le cadmium, le mercure, le cuivre, l'argent, l'or, le bore, le gallium, l'indium, le thallium, les terres rares ou les actinides en mélange avec des métaux réfractaires, des métaux du groupe du fer, des métaux du groupe du platine, du manganèse, technétium, rhénium ou leurs composés
27.
METHOD FOR PRODUCING A HYDROPHILIC SURFACE ON PS/DVB COPOLYMER PARTICLES
The present invention relates to a method for modifying a polymer carrier material for use as a stationary phase in an analytical or preparative separating method, the method comprising the steps of: providing a polymer carrier material, which is at least partly formed of aromatic hydrocarbon compounds comprising at least two vinyl or allyl substituents; producing hydroxy groups on/in the polymer carrier material by means of a method comprising an oxidative treatment of the polymer carrier material and a subsequent reductive or hydrolytic treatment of the reaction product; reacting the product from the previous step with a polyfunctional compound. The invention also relates to a polymer carrier material for use as a stationary phase in an analytical or preparative separating method, in particular a chromatography method, produced according to a method according to the invention.
6665566 or a conversion product thereof which may be obtained by further converting the molybdenum fluoride to another molybdenum compound. In a further aspect, a process for the fluorination of metals or semimetals is provided.
G21G 4/04 - Sources radioactives autres que les sources de neutrons
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Allemagne)
PHILIPPS-UNIVERSITÄT MARBURG (Allemagne)
Inventeur(s)
Worzfeld, Thomas
Offermanns, Stefan
Abrégé
The present invention relates to a composition comprising an inhibitor of plexin-B1 and an inhibitor of plexin-B2, wherein the inhibitor of plexin-B1 and/or the inhibitor of plexin-B2 is/are preferably selected from (i) an inhibitor of the nucleic acid molecule encoding plexin-B1 and/or plexin-B2 selected from a small molecule, an aptamer, a siRNA, a shRNA, a miRNA, a morpholino, a ribozyme, an antisense nucleic acid molecule, a CRISPR-Cas9-based construct, a CRISPR-Cpf1 -based construct, a meganuclease, a zinc finger nuclease, and a transcription activator-like (TAL) effector (TALE) nuclease, and/or (ii) an inhibitor of the plexin-B1 and/or plexin-B2 protein selected from a small molecule, an antibody or antibody mimetic, an aptamer, wherein the antibody mimetic is preferably selected from affibodies, adnectins, anticalins, DARPins, avimers, nanofitins, affilins, Kunitz domain peptides and Fynomers®.
2255) whereat the index x may accept any value between 0.0 and 0.5. The invention further comprises a method for manufacturing the amorphous ion conductive inorganic solid and the use of the amorphous ion conductive inorganic solid for the manufacturing of lithium-ion-batteries.
C03C 3/32 - Compositions de verre ne contenant pas d'oxyde, p. ex. halogénures, sulfures ou nitrures de germanium, de sélénium ou de tellure, binaires ou ternaires
C03C 10/16 - Phase cristalline contenant un halogène
31.
TASK-1 INHIBITORS FOR TREATMENT OF ATRIAL ARRHYTHMIAS
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein R1is ethyl, -H, or methyl and R2is a side chain having a structure as shown in formula (II) wherein X12222, X2to X4222, or R222, for use in treating and/or preventing of atrial arrhythmia in a subject. The present invention further relates to pharmaceutical compositions and kit related to said compound.
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
The invention relates to the provision of a microemulsion containing at least one allergen for allergen immunotherapy of a human or animal patient in respect of allergens such as bee venom, wasp venom, pollen allergens, allergens of dustmites, animal allergens or food allergens, the microemulsion being suitable for dermal application of the allergens. The microemulsion comprises PEG-8 caprylic/capric glycerides, polyglyceryldioleate, and a water phase, an oil phase and at least one allergen dispersed therein. In vivo tests show that with this microemulsion the allergen penetrates the Stratum corneum and passes into the human or animal body. The induction of allergen tolerance by this innovative allergen immunotherapy technique, and thus the clinical efficacy, has already been demonstrated in vivo in the mouse model based on reduced drops in temperature.
The invention relates to multi-functionalized [CD,LM]-annellated perylenes and 2,9-diazaperylenes and their lower and higher homologs, the efficient preparation thereof via triflates and other intermediates of formula (I) wherein X = -OSO2R, and to their use in the field of molecular electronics.
C09B 3/18 - Préparation à partir de substances contenant déjà le noyau pérylène
C09B 5/24 - Colorants à noyau anthracène condensé avec un ou plusieurs hétérocycles avec ou sans carbocycles le(s) hétérocycle(s) étant condensé(s) avec un noyau d'anthraquinone en position 1-2 ou 2-3
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
34.
COVER TO BE ARRANGED ON A MICROTITER PLATE, AND KIT COMPRISING COVER AND MICROTITER PLATE
HELMHOLTZ-ZENTRUM BERLIN FÜR MATERIALIEN UND ENERGIE GMBH (Allemagne)
PHILIPPS-UNIVERSITÄT MARBURG (Allemagne)
Inventeur(s)
Huschmann, Franziska
Wallcher, Dirk
Weiss, Manfred
Klebe, Gerd
Abrégé
The invention relates to a cover (1) to be arranged on a microtiter plate (40), and to a kit having a microtiter plate and such a cover. It is provided that the cover has multiple tiles (20) that correspond to the cavities (41) of the microtiter plate (40) and are arranged on a plate (10), which tiles can be displaced with respect to one another on the plate (10), either directly or indirectly.
The invention relates to a method and a device for determining the electrical conductivity of a solid or liquid material with use of a plasma (low-pressure, normal-pressure or high-pressure plasma) as non-conventional means for contacting the sample to be measured, such that the number of conventional electrical contacts required (for example provided by soldering, welding, bonding) for a conductivity or resistance measurement is reduced.
G01N 27/04 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance
36.
DEVICE AND METHOD FOR DETERMINING THE IMPEDANCE ON A TOOTH
The invention relates to a device and to a method and a device for determining the impedance (alternating current resistance) on a tooth. The impedance is determined by measuring the voltage at a given current intensity or by measuring the current intensity at a given voltage. The determination of the impedance on a tooth is used for diagnosing dental caries.
The illumination unit according to the invention improves the illumination of the work field when applying a composite to a tooth. The illumination unit emits light that is identified as white by the human eye. By means of the selection of the light sources according to the invention and the emitted light wavelengths, the activation of the camphorquinone photoinitiator in the employed composite is delayed, as a result of which a longer processing time for moulding the composite is obtained.
A61C 13/15 - Dispositifs pour le durcissement des prothèses en matière plastique pour le durcissement par action de la lumière
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
A61B 1/24 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour la bouche, c.-à-d. stomatoscopes, p. ex. portant des abaisse-langueInstruments pour ouvrir la bouche ou la maintenir ouverte
F21S 8/02 - Dispositifs d'éclairage destinés à des installations fixes encastrables, p. ex. plafonniers à spots lumineux
F21K 9/64 - Agencements optiques intégrés dans la source lumineuse, p. ex. pour améliorer l’indice de rendu des couleurs ou l’extraction de lumière en utilisant des moyens de conversion de longueur d’onde distincts ou espacés de l’élément générateur de lumière, p. ex. une couche de phosphore éloignée
F21W 131/202 - Éclairage pour un usage médical pour la technique dentaire
A61B 90/30 - Dispositifs pour éclairer une zone chirurgicale, les dispositifs ayant une corrélation avec d’autres dispositifs chirurgicaux ou avec une intervention chirurgicale
The invention concerns a highly efficient molecular white-light emitter. The invention describes amorphous materials that emit a broadband spectrum of light upon irradiation with an infrared laser. Inorganic nanocrystals form the core of the material and are coated with organic ligands on the surface.
C09K 11/66 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du germanium, de l'étain ou du plomb
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
39.
Use of at least one binary group 15 element compound, a 13/15 semiconductor layer and binary group 15 element compounds
4 are independently selected from the group consisting of H, an alkyl radical (C1-C10) and an aryl group, and E and E′ are independently selected from the group consisting of N, P, As, Sb and Bi. This use excludes hydrazine and its derivatives. The binary group 15 element compounds according to the invention allow the realization of a reproducible production and/or deposition of multinary, homogeneous and ultrapure 13/15 semiconductors of a defined combination at relatively low process temperatures. This makes it possible to completely waive the use of an organically substituted nitrogen compound such as 1.1 dimethyl hydrazine as the nitrogen source, which drastically reduces nitrogen contaminations—compared to the 13/15 semiconductors and/or 13/15 semiconductor layers produced with the known production methods.
C23C 16/30 - Dépôt de composés, de mélanges ou de solutions solides, p. ex. borures, carbures, nitrures
C23C 16/22 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le dépôt de matériaux inorganiques, autres que des matériaux métalliques
40.
POLYMERIZATION LAMP AND COMPOSITES FOR FILLING DENTAL CAVITIES
The invention provides novel light-curable composites or composite compositions for filling dental cavities using a novel polymerization lamp (curing lamp). The novel composites or composite compositions have two polymerizable functions, since they contain a first initiator in a small amount and at least one further initiator in a greater amount. The first initiator reacts to different light wavelengths from the at least one further initiator. On irradiation with light for the first initiator the composite is converted to the gel state (preliminary curing), and on subsequent irradiation with the light for the at least one further initiator the composite cures completely (final curing). The invention likewise provides a novel polymerization lamp which emits the light wavelengths needed for the at least two initiators at the required times in the required intensity. The inventive use of the composites having two polymerizable functions or of the composite compositions having two polymerizable functions and of the novel polymerization lamp minimizes polymerization-related stresses in the tooth and filling.
The invention relates to a method and an apparatus for THz time domain spectroscopy. It allows in particular to make full use of the time domain of an ASOPS THz time domain spectrometer, thereby enabling space-resolved measurements at a measurement speed required for industrial applications. A pulse generated by the laser (Ls) at the transmitter end is divided into MxN time-staggered pulses which interact in a spatially resolved manner with the sample (Pr) at different points and generate signals arriving at the detector (E) at the receiver end according to the time staggering scheme. The sub-pulses are time-staggered by means of optical fibers (Z1-Z8) having different lengths as well as additional THz elements, e.g. step wedges (K1-K8).
G01N 21/3586 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant la lumière de l'infrarouge lointainCouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant un rayonnement térahertz par spectroscopie térahertz dans le domaine temporel [THz-TDS]
LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (Allemagne)
PHILIPPS-UNIVERSITÄT MARBURG (Allemagne)
Inventeur(s)
Sutter, Gerd
Song, Fei
Fux, Robert
Volz, Asisa
Becker, Stephan
Eickmann, Markus
Abrégé
The present invention relates to the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) N nucleocapsid protein and/or an immunogenic fragment thereof, or a nucleic acid molecule encoding the MERS-CoV N nucleocapsid protein and/or the immunogenic fragment thereof, for use as a vaccine. The present invention further relates to an immunogenic composition comprising the MERS-CoV N nucleocapsid protein and/or an immunogenic fragment thereof, or a nucleic acid molecule encoding the MERS-CoV N nucleocapsid protein and/or the immunogenic fragment thereof. Furthermore, the present invention relates to a vector comprising a nucleic acid molecule encoding the MERS-CoV N nucleocapsid protein and/or an immunogenic fragment thereof, for use as a vaccine as well as a method of inducing a protective immune response against MERS-CoV.
The invention provides the use of at least one binary group 15 element compound of the general formula R1R2E-E'R3R4 (I) or R5E(E'R6R7)2 (II) as the educt in a vapor deposition process. In this case, R1, R2, R3 and R4 are independently selected from the group consisting of H, an alkyl radical (C1 - C10) and an aryl group, and E and E' are independently selected from the group consisting of N, P, As, Sb and Bi. This use excludes hydrazine and its derivatives. The binary group 15 element compounds according to the invention allow the realization of a reproducible production and/or deposition of multinary, homogeneous and ultrapure 13/15 semiconductors of a defined combination at relatively low process temperatures. This makes it possible to completely waive the use of an organically substituted nitrogen compound such as 1.1 dimethyl hydrazine as the nitrogen source, which drastically reduces nitrogen contaminations - compared to the 13/15 semiconductors and/or 13/15 semiconductor layers produced with the known production methods.
CENTRE TECNOLÒGIC DE LA QUÍMICA DE CATALUNYA (Espagne)
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (Espagne)
UNIVERSITAT POLITÈCNICA DE VALÈNCIA (Espagne)
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (Espagne)
UNIVERSIDAD DE VIGO (Espagne)
FUNDACIÓN HOSPITAL DE MADRID (Espagne)
PHILIPPS UNIVERSITAET MARBURG (Allemagne)
MEDCOMTECH, S.A. (Espagne)
Inventeur(s)
Álvarez Puebla, Ramón Ángel
Fenollosa Esteve, Roberto
Messeguer Rico, Francisco Javier
Rodríguez, Marie Isabelle
Álvarez Rodríguez, Susana
Álvarez Rodríguez, Rosana
Rodríguez De Lera, Ángel
García-Rico Fernández, Eduardo
Yu, Xiang
Carregal Romero, Susana
Parak, Wolfgang Johann
Villanueva Leal, Carlos
Rivera Gil, Pilar
Abrégé
A silicon particle comprising a silicon body, a functionalized silica surface surrounding the silicon body, and a targeting moiety specifically targeting tumor cells, and, optionally, an enzymatically metabolizable compound,is useful in the treatment of cancer by producing cell death after particle internalization.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
The present invention relates to a method of producing itaconic acid. Further the present invention relates to nucleic acids encoding an aconitate-delta-isomerase (ADI) and trans- aconitate decarboxylase (TAD) and uses of such nucleic acids. Provided is additionally a recombinant host cell engineered to overexpress nucleic acids of the present invention. Furthermore an expression cassette and a vector are provided which include the respective nucleic acid.
The invention relates to a method by means of which spatially and temporally separated terahertz sub-pulses having a unique time-location relationship are produced from terahertz pulses, which terahertz sub-pulses open the possibility of spatially resolved measurements by means of THz time-domain spectroscopy. The invention further relates to a measuring device for realizing said method, comprising a THz time-domain spectrometer having an optical unit according to the invention for producing such THz sub-pulses, to a modularly constructed measuring system having at least one such measuring device, and to the use of the method, the measuring device, and the measuring system to detect and localize faults, in particular for non-destructive inline quality inspection in the continuous industrial production of strip-shaped final products, such as paper webs and plastic webs, by means of electromagnetic radiation in the THz range.
G01N 21/89 - Recherche de la présence de criques, de défauts ou de souillures dans un matériau mobile, p. ex. du papier, des textiles
G01N 21/35 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
G01J 3/02 - SpectrométrieSpectrophotométrieMonochromateursMesure de la couleur Parties constitutives
G01J 3/42 - Spectrométrie d'absorptionSpectrométrie à double faisceauSpectrométrie par scintillementSpectrométrie par réflexion
G01N 21/3581 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant la lumière de l'infrarouge lointainCouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant un rayonnement térahertz
The invention relates to the production of an ionic liquid comprising a chalcogenide anion from an ionic liquid comprising a carbonate anion using anion exchange as well as to the use of the obtained chalcogenide compond comprising an organic cation.
C07C 211/63 - Composés d'ammonium quaternaire ayant des atomes d'azote quaternisés liés à des atomes de carbone acycliques
C07C 211/64 - Composés d'ammonium quaternaire ayant des atomes d'azote quaternisés liés à des atomes de carbone de cycles aromatiques à six chaînons
C07C 279/04 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone acycliques d'un squelette carboné
C07C 321/12 - Sulfures, hydropolysulfures ou polysulfures ayant des groupes thio liés à des atomes de carbone acycliques
C07C 381/00 - Composés contenant du carbone et du soufre et comportant des groupes fonctionnels non couverts par les groupes
C07D 213/12 - Préparation par cyclisation utilisant de l'ammoniac, des amines, des sels d'amines ou des nitriles à partir de composés non saturés
C07D 233/56 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés aux atomes de carbone du cycle
H01B 1/12 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisésEmploi de matériaux spécifiés comme conducteurs composés principalement d'autres substances non métalliques substances organiques
Visceral leishmaniasis belongs to the most neglected diseases world-wide and particularly affects the poorest people in developing countries. The disease is caused by protozoan parasites of the genus Leishmania, which cause a series of clinical pictures. One object of the present invention, therefore, is to provide an improved diagnostic tool for the detection of infections with pathogens of the genus Leishmania. With present invention a novel polypeptide from Leishmania donovani is provided, which causes a Leishmania-specific immune reaction. The invention refers to the diagnosis of leishmaniasis, in particular to the diagnosis of visceral leishmaniasis by the use of said new polypeptide. The present disclosure also relates to a vector which carries a nucleotide sequence encoding a polypeptide according to the invention. Furthermore, the invention is directed to a method for the detection of an infection with pathogens of the genus Leishmania.
C07K 14/44 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de protozoaires
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
The invention concerns polymer blends in an aqueous dispersion (latex blends) which, after coating carrier substances, more particularly textiles, form a wash-resistant surface with roll angles of less than or equal to 30° and/or contact angles of greater than or equal to 140°. The polymer blends contain at least one non-fluorinated homopolymer or copolymer (I) with monomers selected from the group of alky lacrylate, alkyl methacrylate, styrene, vinyl chloride, vinyl alkyl ether, vinyl acetate and dimethylsiloxane, and at least one homopolymer or copolymer (II) containing a polyfluorinated component or a polydiorganosiloxane. The very low roll angles or the high contact angles are achieved with a proportion of 2 to 40 mol% for a polyfluorinated component and 30 to 90 mol% for a polydiorganosiloxane relative to the monomer units. The preferred embodiments are polymer blends from homopolymers which have no chemical cross-linkage between the polymer chains. By contrast, hydrophobic polymer blends known from the prior art which are suitable for the wash-resistant finishing of textiles contain complex copolymers or graft polymers, complex, multifunctional monomers and cross-linkages of polymer chains.
C08F 20/24 - Esters contenant des halogènes contenant des radicaux perhaloalkyle
C08L 33/06 - Homopolymères ou copolymères des esters d'esters ne contenant que du carbone, de l'hydrogène et de l'oxygène, l'oxygène, faisant uniquement partie du radical carboxyle
C08L 33/16 - Homopolymères ou copolymères d'esters contenant des atomes d'halogène
D06M 15/277 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone d'acides carboxyliques non saturésLeurs sels ou esters contenant du fluor
50.
EXPRESSION AND SECRETION OF RECOMBINANT, COMPLETELY ASSEMBLED PROTEIN COMPLEXES BY MICROALGAE
The invention relates to a method for the expression and secretion of at least one completely assembled and functional protein complex having medical or biotechnological usefulness in microalgae, wherein the protein complex is an antibody, enzyme, hormone, or vaccine and said protein complex is secreted into the medium.
The present invention provides a process for producing dispersion fibres having covalently bound ionically charged groups. Here, one or two aqueous dispersions of polymer latex particles containing covalently bound ionic groups are mixed with a water-soluble polymer and electrospun. The polymer particles have diameters less than or equal to 200 nm. The electrospinning can be carried out using a single spinning nozzle or parallel and/or layerwise. Crosslinkable particles can optionally be used. Furthermore, dispersion fibres which can be obtained by the process of the invention are provided. The fibres can optionally be crosslinked before, during or after electrospinning, if crosslinkable particles have been used. The dispersion fibres can be used for coating with materials bearing the opposite charge in layer-by-layer processes, in catalysis, in sensor technology, as indicators, in active compound liberation, as antibacterial materials, in photovoltaics and filtration.
The present invention provides a method for producing electro-spun non-woven fabrics with improved adhesion, and non-woven fabrics obtained thereby. For producing the fibres, primary or secondary aqueous dispersions of latex polymer particles are mixed with a water-soluble matrix polymer and processed into fibres by means of dispersion electrospinning. The softening points of the latex polymers of which the particles consist are at least 20°C below the spinning temperature. The spinning temperature is between 0°C and 100°C, advantageously between 20°C and 30°C. A single dispersion or two dispersions at the same time can be spun. If two dispersions are spun simultaneously, this can optionally be done in parallel and/or layer by layer. The latex particles or the fibres obtained therefrom can optionally be cross-linked before, during or after spinning. The present invention also provides non-woven fabrics which can be obtained using the method according to the invention. The non-woven fabrics can optionally be subjected to heat or pressure treatment in order to improve their adhesion to substrates. The non-woven fabrics can be used for special-purpose textiles and for filtration.
D04H 1/728 - Non-tissés formés uniquement ou principalement de fibres coupées ou autres fibres similaires relativement courtes caractérisés par la méthode de formation des voiles ou couches, p. ex. par la réorientation des fibres les fibres étant disposées au hasard par électrofilage
The invention relates to substances which act as selective ligands of nuclear receptors of the PPAR beta/delta sub-type and can be used for treating PPAR beta/delta transmitted illnesses. The substances according to the invention act as inhibitors of the PPAR beta/delta receptor.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61K 31/277 - NitrilesIsonitriles ayant un cycle, p. ex. vérapamil
A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
A61K 31/4995 - Pyrazines ou pipérazines formant une partie de systèmes cycliques pontés
A61K 31/4453 - Pipéridines non condensées, p. ex. pipérocaïne substituées uniquement en position 1, p. ex. propipocaïne, dipérodone
C07C 255/34 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques ayant des groupes cyano liés à des atomes de carbone acycliques d'un squelette carboné contenant au moins un cycle aromatique à six chaînons avec des groupes cyano reliés au cycle aromatique à six chaînons ou au système cyclique condensé contenant ce cycle, par l'intermédiaire de chaînes carbonées non saturées
C07C 255/35 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques ayant des groupes cyano liés à des atomes de carbone acycliques d'un squelette carboné contenant au moins un cycle aromatique à six chaînons le squelette carboné étant substitué de plus par des atomes d'halogène ou par des groupes nitro ou nitroso
C07C 255/37 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques ayant des groupes cyano liés à des atomes de carbone acycliques d'un squelette carboné contenant au moins un cycle aromatique à six chaînons le squelette carboné étant substitué de plus par des groupes hydroxy éthérifiés
C07C 255/42 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques ayant des groupes cyano liés à des atomes de carbone acycliques d'un squelette carboné contenant au moins un cycle aromatique à six chaînons le squelette carboné étant substitué de plus par des atomes d'azote liés par des liaisons simples et n'étant pas liés de plus à d'autres hétéro-atomes
C07C 209/22 - Préparation de composés contenant des groupes amino liés à un squelette carboné par substitution de groupes fonctionnels par des groupes amino par substitution d'autres groupes fonctionnels
54.
METHOD FOR DETERMINING A COMPOSITION OF A PLASTICIZED ELASTOMER MIXTURE BASED ON AT LEAST ONE POLAR OR NON-POLAR RUBBER
The invention relates to a method for determining a composition of a plasticized elastomer mixture based on at least one polar or non-polar rubber, comprising the following steps: irradiating the plasticized elastomer mixture based on the at least one polar or non-polar rubber with electromagnetic waves in the THz frequency range in a test chamber (3) of a THz spectrometer (2); determining at least one actual correlation between the frequency of the emitted electromagnetic waves and a dielectric material property of the elastomer mixture on the basis of received electromagnetic waves; comparing the actual correlations with target correlations by means of an evaluating unit, wherein at least one target correlation of at least one elastomer mixture is stored in the evaluating unit; outputting an information signal if at least one actual correlation deviates from the target correlation of the elastomer mixture.
The invention relates to the use of inhibitors according to general formula I for treating viral infections, in particular for treating influenza infections, for the treatment of inflammatory respiratory tract diseases or for inhibiting serine protease TMPRSS2, wherein X represents CH or N, R1 represents a substituted cyclic sulfonyl radical, R2 represents a non-substituted or substituted amidino group and R3 represents a secondary amide group coupled as an amide.
The invention relates to peptide mimetics comprising the residues P4-P3-P2-P1, which are cyclised between the P3 and P2 amino acid side chains and which, as inhibitors of the serine protease plasmin, are suitable for inhibiting fibrinolysis and thereby for reducing blood loss in hyperfibrinolytic conditions, for example during operations.
The invention relates to a device and to a method for variably changing the propagation time of electromagnetic radiation, such as radiation in the terahertz (THz) range and/or in the optical frequency range. The invention allows a cost-effective, fast and defined propagation time change of the radiation and is thus suitable for use in THz systems that can, for example, be used to test plastic components, fiber composites or food products for flaws. The invention replaces existing technical implementations, which are expensive and slow.
G01J 3/42 - Spectrométrie d'absorptionSpectrométrie à double faisceauSpectrométrie par scintillementSpectrométrie par réflexion
G01N 21/35 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
58.
COMPOUNDS AS PPAR BETA/DELTA INHIBITORS FOR TREATING PPAR BETA/DELTA-MEDIATED DISEASES
The present invention relates to substances that act as selective ligands of nuclear receptors of the PPAR beta/delta subtype and can be used for the treatment of PPAR beta/delta-mediated diseases. The substances of the invention act as inhibitors of the PPAR beta/delta receptor.
C07D 333/38 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/4436 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention provides novel templates for peptide grafting. The template is a modified lasso peptide wherein an amino acid sequence of the wildtype lasso peptide comprising one to five amino acids is substituted by another amino acid sequence comprising one to five amino acids. In the modified lasso peptides according to the present invention, any site of the wildtype lasso peptide can be substituted by another amino acid sequence com- prising one to five amino acids. The term "another amino acid sequence" refers to any amino acid sequence that differs from the amino acid sequence of the respec- tive site in the wildtype lasso peptide. The modified lasso peptides according to the present invention are produced by applying the natural maturation machinery for the processing of lasso peptide pre- cursor variants. These variants are generated on the DNA level of the precursor genes by site-directed mutagenesis. The lasso peptide precursor proteins are het- erologously coexpressed with the two processing enzymes and the ex- port/immunity protein which transform the precursor into the modified lasso variant that is secreted into the culture supernatant from which the modified lasso peptide is extracted and purified. The modified lasso peptides according to the present invention can be used for peptide grafting.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention relates to an imaging THz measurement method, which uses at least one spectral spreading and/or spectral convergence component or uses at least one spectral spreading and/or spectral convergence component in combination with at least one imaging system to convert the frequency information into location information such that the measurement time is decreased and/or fewer mechanical components are needed.
G01N 21/35 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
G02B 26/08 - Dispositifs ou dispositions optiques pour la commande de la lumière utilisant des éléments optiques mobiles ou déformables pour commander la direction de la lumière
61.
ANTENNA FOR TRANSMITTING AND RECEIVING GHZ AND/OR THZ RADIATION WITH AN OPTIMIZED FREQUENCY CHARACTERISTIC
The invention relates to a photoconducting terahertz antenna consisting of a substrate material with a low-resistance applied, preferably concomitantly applied, metal structure for voltage supply or power supply and a photoconducting excitation locus, characterized in that, in addition to the low-resistance structure for voltage supply or power supply, a resonator or a plurality of resonators are also applied in the vicinity of the photoconducting excitation locus, which improves the frequency-selective antenna gain and/or the emission characteristic of the antenna. The properties brought about by the resonators can furthermore be configured such that they can be modulated electrically, optically or by using dielectrics. In addition, such structures can be used as sensor elements, since the resonance response of an antenna according to the invention is sensitive to applied probes.
H01Q 9/28 - Éléments coniques, cylindriques, en cage, en ruban, en treillis ou éléments analogues ayant une surface de rayonnement étendueÉléments comportant deux surfaces coniques ayant le même axe et opposées par leurs sommets et alimentés par des lignes de transmission à deux conducteurs
The invention relates to a synthetic ligand for human anti-Aβ antibodies, comprising at least one peptide unit and at least one stabilization unit covalently bonded to the peptide unit, the sequence of each peptide unit having a sequence analogy of greater than 75% to the complete sequence or to an at least five-member subsequence of the sequence of amino acids 20 to 42 of SEQ ID No. 1. The invention also relates to the use of such a synthetic ligand and to a medicament comprising such a ligand.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61K 38/03 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
63.
SECONDARY AQUEOUS DISPERSIONS OF BIODEGRADABLE DIBLOCK COPOLYESTERS, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF
The present invention provides aqueous stable suspensions of biodegradable diblock copolyesters and a process for preparation thereof. The diblock copolyesters contain a block of an aliphatic polyester and a block of polyethylene oxide. The inventive suspensions comprise aliphatic diblock copolyesters which contain at least one chain segment of an aliphatic polyester and segments of a polyethylene glycol. Aliphatic esters which have been formed by condensation of a saturated alkanedicarboxylic acid and an alkanediol are used. The suspensions are prepared by first dissolving particles of the biodegradable diblock copolyesters in a polar aprotic solvent, then mixing this solution with water and removing the aprotic solvent, and dialyzing the suspension thus obtained against a water-soluble polymer. Optionally, a nonionic surfactant can be added to the secondary suspensions of the biodegradable diblock copolyesters. Inventive suspensions can be used as biodegradable viscosity modifiers, phase mediators in blends, as a adhesives, lacquers, papermaking aids, flame retardants, impact modifiers and hazers of transparent plastics and for production of biodegradable foils, films, fibres, sheets, vessels, pipes and capillaries for transport or packaging purposes. In addition, the inventive suspensions can be used for production of nano- and microfibers and nano- and microfiber nonwovens with unordered or oriented fibres by means of a electrospinning.
C08G 63/672 - Acides dicarboxyliques et composés dihydroxylés
C08L 67/02 - Polyesters dérivés des acides dicarboxyliques et des composés dihydroxylés
D01F 6/86 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiquesLeur fabrication à partir de produits de copolycondensation à partir de polyétheresters
D01D 5/00 - Formation des filaments, fils ou similaires
64.
METHOD FOR PRODUCING DIALKYL CARBONATES, COPPER-CONTAINING CATALYST AND USE OF A COPPER-CONTAINING CATALYST
The invention relates to a method for producing a dialkyl carbonate, in which an alkanol is reacted with carbon monoxide and oxygen in the presence of a copper-containing catalyst which is supported on a solid phase substrate, wherein according to the invention the catalyst is present on the solid phase substrate under method conditions in a liquid catalyst phase, and the catalyst comprises at least one copper-containing complex compound. Moreover, the copper-containing catalyst is supported on a solid phase substrate and is present in a catalyst phase which has a melting point of less than 120ºC. A copper-containing complex compound belonging to the catalyst comprises at least one nitrogen(III) compound as an N-donor ligand and/or a quaternized nitrogen(III) compound as an organic cation. The nitrogen(III) compound is selected from the group of N -alkylimidazoles, N,N -dialkylamino pyridines, N-alkylpyrazoles or N alkyl-penta-organoguanidines. The invention further relates to the use of a catalyst in an oxidative carbonylation.
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
C07C 68/00 - Préparation des esters de l'acide carbonique ou de l'acide formique halogéné
The invention relates to mutations in the Flo5A domain of flocculins of industrial yeasts, said mutations leading to a desired modification of the substrate specificity and of flocculin proteins. In particular, the Flo5A-Q98A mutant surprisingly exhibits in vivo a NewFlo type of flocculation inhibition, by means of an inhibition by glucose as well, but without completely losing the flocculation ability. The invention further relates to a method for detecting Flo5-carrying yeast cells in a cell suspension.
C07K 14/395 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de champignons provenant de levures provenant de Saccharomyces
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
66.
HEXAORGANO GUANIDINIUM ORGANOCARBONATES, THE PRODUCTION OF SAME AND THE USE THEREOF
The invention relates to hexaorgano guanidinium organocarbonates according to formula (I), to a method for the production of same, and to the use thereof. To this end, R1 to R5 denote alkyl, allyl, vinyl, benzyl, aryl or heteroaryl; wherein the groups R1 and R2, R3 and R4 or R2 and R3, also jointly with nitrogen atoms of the guanidine skeleton, can form cyclical secondary amino groups, R6 denotes alkyl, benzyl or allyl, and R7 denotes alkyl, benzyl, allyl, aryl or heteroaryl. The hexaorgano guanidinium organocarbonates according to the invention are produced by reacting a pentaorgano guanidine with a diorganocarbonate, wherein the reaction can be carried out in solution or in the gas phase. The method according to the invention is atom-economical and avoids the formation of by-products. The hexaorgano guanidinium organocarbonates can be used to produce other hexaorgano guanidinium salts. By the reaction with an acid or an acid salt, anion metathesis occurs with decarboxylation of the organocarbonate. In this way, the reaction equilibrium is shifted to the product side. Both the hexaorgano guanidinium organocarbonates according to the invention and the hexaorgano guanidinium salts obtainable therefrom are highly pure, in particular halide-free, ionic liquids.
C07C 279/04 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone acycliques d'un squelette carboné
C07C 279/18 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone de cycles aromatiques à six chaînons
67.
METHOD FOR DETERMINING THE ACTIVITY OF TRANSGLUTAMINASE FACTOR XIIIA
The invention relates to a UV/Vis or fluorescence-based method for qualitatively and quantitatively determining the activity of blood coagulation factor XIIIa or the content of the zymogen, factor XIII, which is activated to form factor XIIIa, using novel chromogenic or fluorescence-labeled peptide substrates and to the use of such methods and/or substrates in screening assays. The peptide substrates according to the invention can optionally contain a quencher/donor pair.
C12Q 1/52 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase une transaminase
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
68.
POLYMERIC OR OLIGOMERIC ACTIVE INGREDIENTS HAVING A BIOCIDAL EFFECT, METHOD FOR THE PRODUCTION THEREOF, AND COMPOSITION COMPRISING A POLYMERIC OR OLIGOMERIC ACTIVE INGREDIENT
The invention relates to novel polymeric or oligomeric active ingredients having a biocidal effect. Such especially advantageous polymeric or oligomeric active ingredients having a biocidal effect can be obtained by polycondensating a guanidine acid addition salt with an amine mixture, which contains at least one diamine and/or one triamine, wherein at least one amine is selected from the group comprising i) diamine, which has at least one alicyclic group, and ii) dialkylenetriamine. At least one amine is preferably selected from 4,4'-methylene-bis(cyclohexylamine) and diethylenetriamine. In addition, it is favorable if the guanidine acid addition salt is guanidine hydrochloride.
The present invention relates to novel lithium salts which comprise pentafluorophenylamide anions and are of the general formula Li+[N(SO2-R)(C6F5)]-, which are optionally present as solvent-free complexes. R is selected from fluorine, linear or branched, acyclic or cyclic alkyl groups having 1 to 20 carbon atoms, which are unfluorinated, partly fluorinated or fully fluorinated; or unfluorinated, partly fluorinated or fully fluorinated aryl or benzyl groups having up to 20 carbon atoms. The inventive lithium salts are prepared by reacting the corresponding NH acid of the pentafluorophenylamide with one equivalent of lithium bis(trimethylsilyl)amide or lithium organyl, the reaction advantageously being performed in the presence of apolar aprotic solvents. In this way, lithium salts are obtained in the form of solvent-free complexes. These solvent-free lithium complexes are thermally stable, electrochemically stable and stable to oxidations, and have a high ion conductivity. The inventive lithium salts can be used as ion-conducting materials, electrically conductive materials, dyes, and in chemical catalysis. They are preferably used as ion-conducting electrolytes in lithium ion accumulators.
C07C 303/34 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfuriques
C07C 303/40 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par des réactions n'impliquant pas la formation de groupes sulfonamide
C07C 307/02 - Monoamides d'acides sulfuriques ou de leurs esters, p. ex. acides sulfamiques
C07C 311/08 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
C07C 311/09 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé le squelette carboné étant substitué de plus par au moins deux atomes d'halogène
C07C 311/10 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné saturé contenant des cycles
C07C 311/21 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 10/0568 - Matériaux liquides caracterisés par les solutés
Staatliches Weinbauinstitut der Landwirtschaftsverwaltung Baden-Württemberg (Allemagne)
Inventeur(s)
Greiner, Andreas
Wendorff, Joachim, H.
Hellmann, Christoph
Breuer, Michael
Leithold, Günter
Hummel, Hans, E.
Hein, Detlef
Agarwal, Seema
Abrégé
The present invention relates to a device for spreading active agricultural agents, wherein the device can be brought to the site of action temporally and spatially separated from the production process and comprises a dispenser as well as non-water-soluble nanofibers and/or mesofibers storing active agricultural agents. The polymers of which the nanofibers or mesofibers consist are preferably biodegradable. The active agricultural agents are selected from the group consisting of fungicides, herbicides, bactericides, plant growth regulators and plant nutrients. They are preferably pheromones, kairomones, and signal substances. The invention further discloses a method for producing said device, wherein the nanoparticles and/or mesofibers storing active agents are produced by means of electrospinning. The device can be used to bring active agricultural agents to the site of action thereof temporally and spatially separated from the production process. The spreading can be done mechanically or automatically. The site is preferably a useful area from pomiculture, viticulture, horticulture or a commercial row crop. The device according to the invention is particularly suited for controlling arthropods.
D01F 1/10 - Autres agents modifiant les propriétés de ces filaments
D01F 6/84 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiquesLeur fabrication à partir de produits de copolycondensation à partir de copolyesters
D01D 5/00 - Formation des filaments, fils ou similaires
The invention relates to describing and applying gene sequences and the expressed proteins or protein sequences of the cytokine-dependent transcription factor STAT1 and the homologous sequences in other STAT transcription factors, and the protein sequences thereof, having an increased affinity, relative to the wild type of STAT transcription factors, for corresponding DNA sequences due to improved specific recognition of the corresponding DNA sequences. By identifying the underlying molecular mechanism for dissociating the STAT transcription factors from the corresponding DNA sequences, the invention enables improved verification of the activation state of each STAT transcription factor.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention relates to a device and to a method for milling fibers. To this end, a grinding operation of the fibers is employed. Short fibers (approx. 10 to 30 µm) are produced. It is possible to use fibers susceptible to water. The short fibers are provided with a medical active substance and can be inhaled after the process has been concluded.
D01G 1/00 - Découpage des filaments continus ou des fibres longues, p. ex. mise sous forme de fibres coupées
B29B 13/10 - Conditionnement ou traitement physique de la matière à façonner par broyage, p. ex. par triturationConditionnement ou traitement physique de la matière à façonner par tamisageConditionnement ou traitement physique de la matière à façonner par filtration
73.
METHOD, PARTICULARLY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), FOR IN VITRO DETECTION OF AMYLOID BETA AUTOANTIBODIES, MICROTITER PLATE, AND TEST KIT
A method, particularly an enzyme-linked immunosorbent assay (ELISA), for the in-vitro detection of Aβ autoantibodies in human serum and/or plasma contains the following steps: preparing an antigen-coated solid phase; incubating the solid phase with a blocking solution; incubating the solid phase with a sample to be examined; immunological detection of the Aβ autoantibodies on the solid phase; and reading the detected results of the solid phase using a reading tool. According to the invention, the preparation of the antigen-coated solid phase advantageously includes incubating the solid phase with a coating solution in which the antigen is dissolved, said antigen having a peptide sequence selected from the group SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
74.
RESPIRATION MEASUREMENT DEVICE AND METHOD FOR THE OPERATION THEREOF
The invention relates to a method (23) for actuating a measuring device (1) for detecting physiological values of the respiration of a person (9), the measuring device (1) outputting different gas mixtures during different measurement phases (28, 29, 30, 31). During a main measurement phase (30), the concentration of at least one first gas of the gas mixture is held constant at least temporarily, and the concentration of at least one second gas of the gas mixture is changed at least temporarily. A plurality of individual measurement values is further detected during the main measurement phase (30), the individual measurement values each being stored in an individual data set.
The invention relates to the use of inhibitors of the general formula (I) where R1 is a substituent, P3 is a mono- or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the D configuration, P2 is a mono- or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the L configuration, and P1 is an arginine mimetic, the basic group of which may optionally also be present as a prodrug, for inhibition of the serine proteases HAT and TMPRSS2 for treatment of viral infections, for treatment of inflammatory respiratory pathway disorders or for treatment of tumors and prevention of metastases.
The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 µm and lengths of 1 µm to several meters. The invention further relates to a method for producing said composite materials. Polymer nanoparticles can be produced in different ways, such as through controlled precipitation of a polymer solution that optionally comprises a loading substance. The nanoparticles are then mixed with another polymer and a loading substance as applicable, depending on whether particles, fibers or both are to be loaded with substance. The processing of this solution into composites comprising polymer fibers polymer nanoparticles can occur by means of electrospinning, melt spinning, extruding or template process. Composite materials according to the invention are suitable for the production of pharmaceuticals that release therapeutically or diagnostically effective substances slowly and in a controlled manner.
The present invention discloses a method for producing metal-containing nanoparticles enveloped with polymers and to particles that can be obtained therefrom. In the method according to the invention, at least one anionic polymerizable monomer is polymerized at room temperature in the presence of an anionic macroinitiator. Then, first an aliphatic or aromatic sulfide is added, thereafter a solution of at least one organosoluble metal salt in an aprotic organic solvent, and finally a homogeneous reducing agent. Metal-containing nanoparticles are created, which are covalently bound to the growing anionic polymerides. The metal salts are preferably salts of silver, copper, gold, tin, lead, chromium or zinc, or mixtures thereof. Anionic polymerizable monomers are, for example, styrene (St), butadiene, isoprene, ethylene oxide, propylene oxide, caprolactone, lactide, glycolide, acrylates, methacrylates, bisacrylates, cyanoacrylates, amides, siloxanes, vinyl pyridines or acrylonitrile. The particles according to the invention can be used to provide polymers in textiles and materials with an antibacterial finish. Furthermore, they are suited for producing inks. If the underlying metals are such which exhibit plasmon resonance, the particles can also be used in sensors utilizing the plasmon resonance effect. The metal-containing nanoparticles which are enveloped with polymers and accessible by using the method according to the invention do not aggregate or agglomerate, and the physical and chemical properties thereof remain unchanged for extended periods.
C08F 20/18 - Esters des alcools ou des phénols monohydriques des phénols ou des alcools contenant plusieurs atomes de carbone avec l'acide acrylique ou l'acide méthacrylique
The invention relates to a non-viral transfection agent comprising polymer/nucleic acid complexes and nanofibers, wherein the polymer/nucleic acid complexes are composed of at least one nucleic acid and at least one cationic polymer. The nanofibers carry the polymer/nucleic acid complexes, wherein the non-viral transfection agent is advantageously produced by means of electrospinning. The cationic polymer is favorably a polyimine or polyethyleneimine and can be modified with one or more hydrophilic polymers coupled thereto. It can also be advantageous to couple the cationic polymer with one or more carbohydrates and/or with a receptor-specific ligand. The nucleic acid is a DNA or an RNA, or a DNA or RNA derivative, advantageously a therapeutically active nucleic acid. The nanofibers are composed of biodegradable, biocompatible polymers. The nanofibers or the entire transfection agent can be provided with a polymer coating. A method for producing a non-viral transfection agent comprises the following steps: providing the polymer/nucleic acid complex, producing a spinning solution containing the polymer/nucleic acid complexes, and electrospinning.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
79.
METHOD FOR PRODUCING PHOTO-CROSSLINKABLE NANOPARTICLES IN A CONTINUOUS REACTOR
The present invention relates to a method for producing photo-crosslinkable polymer nanoparticles having diameters less than or equal to 100 nm and polymer nanoparticle dispersions that can be obtained therefrom. For this purpose, monovinyl compounds are radically copolymerized with divinyl compounds in the presence of an anionic surfactant in a continuous reactor. The monovinyl compounds are, for example, acrylates, methacrylates, styrenes, vinyl acetate, acrylonitrile, monohalogen ethylenes, dihalogen ethylenes, trihalogen ethylenes, tetrahalogen ethylenes, maleic anhydrides, and oxepanes. The divinyl compounds are, for example, divinylstyrene, butadiene, isoprene, allyl acrylates, allyl methacrylates, cyanoacrylic acid allyl ester, and unsaturated polyester. The anionic surfactant is preferably sodium lauryl sulfate. The polymer nanoparticles thus obtained can then be processed together with a non-ionic surfactant and a matrix polymer to form an aqueous polymer nanoparticle dispersion. The non-ionic surfactant or matrix polymer is, for example, PEG or PVA. Polymer fibers can be produced from said polymer nanoparticle dispersions by means of electrospinning. The polymer nanoparticles that can be obtained using the method according to the invention and the fibers that can be produced from the nanoparticles can be used as polymer additives for varying rheological properties, for varying glass transition points, for varying the wetting behavior, and for modifying the surface of polymers.
C08F 2/26 - Polymérisation en émulsion utilisant des agents émulsifiants anioniques
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
D01D 5/00 - Formation des filaments, fils ou similaires
D01F 1/10 - Autres agents modifiant les propriétés de ces filaments
C08F 20/00 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et un seul étant terminé par un seul radical carboxyle ou un sel, anhydride, ester, amide, imide ou nitrile
The present invention relates to electrospun polymer fibers comprising bacteria-containing hydrogel particles. Bacteria-containing hydrogel particles are produced in that water-soluble polymers are cross-linked into hydrogels and mixed with a bacteria suspension. The cross-linking can be carried out either chemically before adding the bacteria suspension or physically before or after the addition thereof. Thereafter, said hydrogel particles are spun into fibers or nonwoven fabrics together with a solution of an electrospinnable polymer. In the dry state without the addition of water or a cell culture medium, the bacteria present in said hydrogel particles, or in the electrospun polymer fibers comprising said particles, are viable for a long time (several months) and, at the same time, protected against the influence of solvents that otherwise would kill them, such as alcohols, acetone, chlorinated hydrocarbons, ethers, and toluene. Through contact with water, the bacteria can be released again at any time and multiply under conventional culturing conditions. The electrospun polymer fibers according to the invention comprising bacteria-containing hydrogels can be used for the dry storage of useful bacteria or for killing harmful bacteria. For example, they can be applied to textiles and membranes. However, they can also be used for applications in wastewater treatment, in the protection of the environment (preservation of water systems), in the agricultural and foodstuffs sector, in pharmacy, fermentation and the construction sector.
C12N 1/04 - Conservation des micro-organismes à l'état viable
C12N 11/04 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique piégées à l’intérieur du support, p. ex. dans un gel ou dans des fibres creuses
81.
MEANS FOR SEPARATING MICROORGANISMS ON THE BASIS OF ELECTROSPUN FIBERS
The invention relates to composite filters for separating microorganisms from liquids that are contaminated therewith. Composite filters of the invention comprise at least one porous, liquid-permeable support material and at least one nonwoven made from electrospun fibers. The support materials are selected from among fiber-oriented nonwovens, matted nonwovens, porous solids, tissues, paper filters, plastic filters, metal screens, and membrane filters. The electrospun fibers can be water-stable polymer fibers made of synthetic polymers or biopolymers, metal fibers, metal oxide fibers, carbon fibers, or ceramic fibers. In order to produce the composite filters, at least one nonwoven fabric is deposited on the support material/s using the electrospinning technique. The microorganisms that can be separated from liquids contaminated therewith using the composite filters of the invention include archaea, bacteria, viruses, fungi, and protozoa. They also include algae and viruses if they are unicellular organisms or multicellular clusters which are not larger than 0.2 mm. The composite filters of the invention can be used for separating microorganisms from cell culture liquids, industrial and private wastewater and process water, blood plasma, blood serum, and cooling lubricants.
The invention relates to multi-base, N-terminally modified tetrapeptide mimetics having a C-terminal P1 arginine mimetic, to a method for producing the same and to the use thereof in the therapy and prophylaxis of diseases that are caused by bacterial pathogens or viruses, and in the therapy and prophylaxis of diabetes, arteriosclerosis, cancer, Alzheimer's or the development of overweight, and to the use of the compounds as inhibitors of proprotein convertases which cleave downstream of basic P1 residues, especially for inhibiting furin protease.
The present invention provides an apparatus and a method for distinguishing enantiomers with the aid of broadband femtosecond circular-dichroism laser-ionization mass spectrometry. In this case, an fs laser system is used, the laser pulse duration (τ) of which is less than or equal to 200 fs, with respect to a bandwidth-limited pulse, and the central wavelength (λ) of which is in the range between 200 nm and 1.100 nm. The spectral bandwidth of the laser pulse is chosen from bandwidths of less than or equal to 40 nm and those of more than 40 nm. The laser pulses are circular-polarized, in which case it is possible to change between right-hand and left-hand circular-polarized light. The circular-polarized fs laser pulses are used directly for ionization, wherein the light material interaction is enantiomium-specific. There is therefore no need for separation of substance mixtures. The wavelength which is appropriate for ionization of a specific analyte need never be known in advance: for bandwidths of less than or equal to 40 nm, the wavelength is varied in order to determine the appropriate wavelength. For bandwidths of more than 40 mm, the wavelength which is appropriate for the respective molecule is intrinsically contained in the spectrum. The sample to be examined and an achiral reference substance are examined simultaneously in the flight-time mass spectrometer for both circular polarizations. For a given ionization wavelength and polarization of the laser pulse, each flight-time mass spectrum obtained in this way was not only substance-specific but also enantiomium-specific. The apparatus according to the invention and the associated method combine CD spectroscopy and mass spectrometry and are suitable for identification and examination of enantiomers even in previously unknown substance mixtures.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Fallahi, Mahmoud
Moloney, Jerome, V.
Koch, Stefan, W.
Koch, Martin
Baaske, Kai
Scheller, Maik, Andre
Fan, Li
Abrégé
The invention relates to a method and a device for generating electromagnetic radiation in the terahertz and millimeter range, using a non-linear medium generating the indicated radiation by differential frequency generation within the laser resonator of a suitable laser, such as a VECSEL or a disc laser operating in two or more color modes. The invention further relates to novel decoupling structures used to this end for optimized decoupling and separating of the generated radiation from the optical radiation generated in the laser resonator, and suitable novel non-linear media as such.
H01S 1/02 - Masers, c.-à-d. dispositifs utilisant l’émission stimulée de rayonnement électromagnétique dans la gamme des micro-ondes solides
H01S 3/108 - Commande de l'intensité, de la fréquence, de la phase, de la polarisation ou de la direction du rayonnement, p. ex. commutation, ouverture de porte, modulation ou démodulation par commande de dispositifs placés dans la cavité utilisant des dispositifs optiques non linéaires, p. ex. produisant une diffusion par effet Brillouin ou Raman
H01S 3/07 - Structure ou forme du milieu actif consistant en une pluralité de parties, p. ex. segments
H01S 3/08 - Structure ou forme des résonateurs optiques ou de leurs composants
H01S 3/082 - Structure ou forme des résonateurs optiques ou de leurs composants comprenant trois réflecteurs ou plus définissant une pluralité de résonateurs, p. ex. pour la sélection ou la suppression de modes
H01S 5/183 - Lasers à émission de surface [lasers SE], p. ex. comportant à la fois des cavités horizontales et verticales comportant uniquement des cavités verticales, p. ex. lasers à émission de surface à cavité verticale [VCSEL]
H01S 5/40 - Agencement de plusieurs lasers à semi-conducteurs, non prévu dans les groupes
The present invention provides novel hydrolytically decomposable ionic copolymers. These ionic copolymers are made up of a cyclic ketene acetal A, an anionic or cationic methacrylic acid derivative B selected from 2-methyl-methacrylate, [2-(2-methyl-1-methylen-allyloxy)-ethane sulfonate, [2-(2-methyl-1-methylen-allyloxy)ethyl]-phosphonate or a quaternary amine of N,N-dimethylaminoethylmethacrylic acid (DMAEMA) and optionally a neutral methacrylic acid derivative C. According to the invention, hydrolytically decomposable ionic copolymers are produced by polymerizing the components A, B and C in the presence of a radical starter under a protective gas atmosphere, followed by purification. All copolymers according to the invention are hydrolytically decomposable. Copolymers containing a maximum of 40 mol-% of ester groupings in the backbone are also biodegradable, wherein in the case of cationic copolymers a maximum of 20 mol-% quaternized DMAEMA may be present. Cationic copolymers containing at least 50 mol-% of component B are antimicrobial. Both anionic as well as cationic copolymers are suitable for the production of nanoparticles. Cationic copolymers can be used a superhydrophobic materials as well as adhesives. Anionic copolymers are suitable as biodegradable thermoplastic elastomers and as biodegradable ionomers.
C08F 8/44 - Préparation de sels métalliques ou de sels d'ammonium
C08F 216/38 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par un radical alcool, éther, aldéhyde, cétone, acétal ou cétal par un radical acétal ou cétal
The invention relates to a feeding device (1, 14, 21, 28, 38) for feeding a lead unit (7) to a through-opening (6) of a medical treatment device (2, 30). The feeding device (1, 14, 21, 28, 38) comprises a guide unit (11, 29) which leads the lead unit (11, 29) when the latter is fed to the feeding device (1, 14, 21, 28, 38) and a connecting unit (9, 32) which connects the medical treatment device (2, 30) to the feeding device (1, 14, 21, 28, 38) in the correct position.
The invention relates to homoleptic, ortho-metalated, chelate-stabilized benzylamine complexes of the rare earth elements. The rare earth elements are selected from the group including Sc, Y, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu. At least one benzylic proton of the benzylamine ligand in the complexes according to the invention is replaced by an alkyl or aryl group. The preferred complexes are complexes in which both benzylic protons of the benzylamine ligand are replaced by alkyl or aryl groups. The complexes according to the invention are produced by reacting chelate-stabilized rare earth halides with ortho-lithiated aryl ligands at room temperature in a protective atmosphere. The complexes according to the invention are thermostable and are suitable as catalysts for the hydroamination of olefins.
The invention relates to cyclopentadienylphosphazene complexes (CpPN complexes) of metals of the III. and VI. group and of the lanthanoids except for lutetium. The complexes of the invention are isolobal and isoelectric with respect to the [(CpSiN)TiR2] complexes. There is exactly one CpPN moiety in the complexes of the invention. The cyclopentadienyl moiety of CpPN represents a monodentate, anionic ligand of the metal atom in all complexes of the invention. The metal atom is also bound to other anionic ligands. In a preferred embodiment, both the cyclopenadienyl moiety and the nitrogen atom within CpPN bind to the metal atom so that CpPN represents a bidentate ligand. Complexes in which CpN represents a bidentate ligand are CpPN Constrained Geometry Complexes (CpPN-CGC). The invention also relates to methods for producing the complexes in situ. The CpPN complexes can be electrically neutral or be present as cationic complexes. Cationic complexes are formed when one of the other anionic ligands of the metal atom is replaced by a neutral ligand; counterions of the cationic CpPN complexes are preferably fluoroborate, tetraphenyl borate, tetrakis-(3,5-trifluormethylphenyl)borate. The complexes are produced in situ by reacting a metal halide with a protonated cyclopentadienylphosphazene CpPNH and an alkaline or alkaline earth salt of the desired other anionic ligand. The complexes according to the invention can be used as catalysts for the hydroamination and polymerization of polyolefins.
C07F 9/6581 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore et d'azote, avec ou sans atomes d'oxygène ou de soufre, comme hétéro-atomes du cycle
Squamous cell carcinomas of the head and neck region (HNSCC) form a group of metastasizing tumours with a high mortality rate in humans and animals. Since it has been discovered that the biomolecule ozone inhibits the growth of various carcinoma cells in vitro, we have used the highly aggressive and lethal VX2 carcinoma of the New Zealand rabbit as HNSCC tumour model in order to test whether ozone has antitumour effects in vivo. Therapeutic insufflation of a medical ozone/oxygen (O3/O2) gas mixture into the peritoneum (O3/O2 pneumoperitoneum) at an advanced stage of a neoplastic disease led to a survival rate of 7/14 rabbits. Six of the seven surviving rabbits showed a complete tumour regression and the absence of local or remote pulmonary metastases. Insufflation of pure oxygen (O2) led to a survival rate of 3/13 animals, which was associated with complete tumour remission in two of the three surviving animals. Of the fourteen sham-treated animals, only one developed spontaneous tumour remission and survived. No side effects or changes in standard blood parameters were observed after repeated intraperitoneal insufflations with O3/O2 or O2 gas. Animals with O3/O2-induced tumour regression developed tolerance to reimplantation of the VX2 tumour. It was possible to reverse this by immunosuppression with a combination of dexamethasone and cyclosporin A, suggesting that the O3/O2-mediated activation of the body's immune surveillance has an antitumor effect. Although the exact mechanisms of action are still unclear, the available data indicates that O3/O2 pneumoperitoneum is a promising new strategy in tumour therapy.
The present invention describes a simple mutant of natural asparagine oxygenase, wherein said simple mutant comprises at least the amino acids 13 through 318 of the natural asparagine oxygenase AsnO. In said protein according to the invention comprising at least the amino acids 13-318 from AsnO D241 N, the residual amino acid at position 241 of the natural asparagine oxygenase AsnO is exchanged from aspartate (D) to asparagine (N). The protein according to the invention comprising at least the amino acids 13-318 of AsnO D241 N is produced by a directed mutagenesis of the AsnO wild type, cloning of the expression plasmid into a vector, transformation of the vector plasmid construct into a host organism, and expression of the recombinant protein. The protein according to the invention is suitable for chemoenzymatic and enantioselective production of L-threo-hydroxyaspartate from L-aspartate. The protein is substrate specific, and quantitatively converts L-aspartate to L-threohydroxyaspartate.
METHOD OF CLONING AT LEAST ONE NUCLEIC ACID MOLECULE OF INTEREST USING TYPE IIS RESTRICTION ENDONUCLEASES, AND CORRESPONDING CLONING VECTORS, KITS AND SYSTEM USING TYPE IIS RESTRICTION ENDONUCLEASES
The present invention refers to methodsof (sub)cloning at least one nucleic acid molecule of interest. One embodiment relates to a method of (sub)cloning at least one nucleic acid molecule of interest comprising a) providing at least one (replicable) Entry vector into which the at least one nucleic acid molecule of interest is to be inserted, wherein the at least one Entry vector carries two recognition sites for at least one first type IIS and/or type IIS like restriction endonuclease and wherein said at least one nucleic acid molecule of interest can be excised from the at least one Entry vector at two combinatorial sites with one (same) or more (different) cohesive ends that are formed by the at least one first type IIS or type IIS like restriction endonuclease, and b) providing an Acceptor vector, into which the at least one nucleic acid molecule of interest is transferred from the at least one Entry vector carrying the at least one nucleic acid molecule of interest, wherein said Acceptor vector comprises at least one recognition site for at least one second type IIS restriction endonuclease and/or at least one recognition sites for at least one type IIS like restriction endonuclease, and wherein said Acceptor vector provides two combinatorial sites identical to the two combinatorial sites present in the Entry vector. The inventions also relates respective cloning vector and kits.
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
The invention relates to composite fibers comprising ionically functionalized nanofibers or mesofibers and oppositely charged ionically functionalized particles which are applied to the surface of the fibers, a method for producing said composite fibers, and the use thereof. The nanofibers or mesofibers are composed of non-ionic polymers, carbon, polyelectrolytes, ionomers, ceramic materials, or metals. Production of the composite fibers according to the invention: polyelectrolytes and ionomers naturally have ionic groups on the surface; with the other fiber materials, ionic groups are produced, treated with a particle dispersion comprising oppositely charged, ionically functionalized particles, resulting in nanofibers or mesofibers, to the surface of which particles are applied. The ionically functionalized particles are preferably mesoparticles or nanoparticles and are selected from among non-ionic polymer particles, ionic polymer particles, ionomer particles, metal particles, carbon materials, pigments, magnetic particles, biological particles. The composite fibers according to the invention comprising ionically functionalized mesofibers or nanofibers and, on the surface thereof, oppositely charged ionically functionalized particles can be used for filter media and separation media, for finishing fabrics, releasing active substances, thermally insulating, protecting plants, in solar energy, sensor technology, and as thermoelectric materials, for example.
D06M 11/83 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec des métauxTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec des composés libérant des métaux, p. ex. des métaux-carbonylesRéduction de composés métalliques sur des textiles
D06M 23/08 - Procédés dans lesquels l'agent traitant est appliqué en poudre ou sous forme granulaire
D06M 23/12 - Procédés dans lesquels l'agent traitant est incorporé dans des microcapsules
B01D 39/16 - Autres substances filtrantes autoportantes en substance organique, p. ex. fibres synthétiques
B01D 39/20 - Autres substances filtrantes autoportantes en substance inorganique, p. ex. papier d'amiante ou substance filtrante métallique faite de fils métalliques non-tissés
H01F 1/00 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques
93.
METHOD AND DEVICE FOR FIXING AND/OR MANIPULATING TISSUE
The invention relates to a device for fixing and manipulating tissues of the kind that can be fixed at least temporarily by suction. Tissues in this connection are to be understood not just as organic tissues, for example the tissues of living beings, but also as inorganic tissues, such as films or textiles. The invention relates in particular to a device for fixing and manipulating tissues that surround sensitive organs, for example like the pericardium in humans. The invention further relates to a method for fixing and manipulating, and in particular for puncturing, such tissues or the areas lying beneath them.
The invention relates to a method for producing polymer fibers, especially nano- and mesofibers, according to the electrospinning technique, wherein an aqueous solution including polyelectrolytes of opposite charge is electrospun. The fibers obtained according to said technique are stable in water. The solution to be spun can optionally contain at least one nonionic surfactant and/or at least one water-soluble polymer. The invention also relates to the fibers that can be obtained by said method.
D01D 5/00 - Formation des filaments, fils ou similaires
D01F 6/44 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiquesLeur fabrication à partir de mélanges de polymères obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone comme constituant majeur avec d'autres polymères ou des composés de bas poids moléculaire
D01F 6/88 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiquesLeur fabrication à partir de mélanges de produits de polycondensation comme constituant majeur avec d'autres polymères ou des composés de bas poids moléculaire
95.
METHOD FOR PRODUCING SELF-ASSEMBLED MONOLAYERS ON SOLID BODY SURFACES
The present invention relates to a method for producing self-assembled monolayers (SAMs) on solid body surfaces, wherein impurities of the surfaces are minimized by the use of solvents and/or oxygen. The substances to be assembled are evaporated and vapour deposited in the oxygen-free gas stream onto the solid body surface to be coated at pressures ranging between 10-6 and 10-8 mbar. Conventional methods in which SAMs are deposited from a solution require deposition times ranging from some hours to several days. The inventive method, however, allows the deposition of monolayers within 30 to 60 minutes.
B05D 7/24 - Procédés, autres que le flocage, spécialement adaptés pour appliquer des liquides ou d'autres matériaux fluides, à des surfaces particulières, ou pour appliquer des liquides ou d'autres matériaux fluides particuliers pour appliquer des liquides ou d'autres matériaux fluides particuliers
B05D 3/02 - Traitement préalable des surfaces sur lesquelles des liquides ou d'autres matériaux fluides doivent être appliquésTraitement ultérieur des revêtements appliqués, p. ex. traitement intermédiaire d'un revêtement déjà appliqué, pour préparer les applications ultérieures de liquides ou d'autres matériaux fluides par cuisson
The invention relates to composite fibres consisting of polymer fibres and bacteria, produced by an electrospinning method. The composite fibres according to the invention permit the application scope of polymer fibres to be increased by the use of enzyme-active bacteria.
D01D 5/00 - Formation des filaments, fils ou similaires
D01F 1/10 - Autres agents modifiant les propriétés de ces filaments
D01F 6/66 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiquesLeur fabrication à partir de produits d'homopolycondensation à partir de polyéthers
C08L 99/00 - Compositions contenant des composés macromoléculaires naturels ou leurs dérivés, non prévus dans les groupes ou
C08L 101/00 - Compositions contenant des composés macromoléculaires non spécifiés
97.
SALTS CONSISTING OF PENTAFLUORPHENYLIMIDE ANIONS AND THEIR USE AS IONIC LIQUIDS
The present invention relates to novel, only slightly basic fluorinated pentafluorophenylimide anions of general formula (I), which can be used as anions in ionic liquids. In said formula, R1 represents a linear or branched, non-fluorinated or partially or completely fluorinated aryl group, a 2-nitroaryl group, a 4-nitroaryl group, a 2,4-dinitroaryl group, a non-fluorinated, partially fluorinated or completely fluorinated benzyl groυp, or stands for CN, CO-H, a CO-aryl group or a CO-alkyl group or R1 = -SO2-R2, and R2 represents a branched or unbranched alkyl group comprising between 1 and 20 C atoms or an aryl or benzyl group and said alkyl, benzyl or aryl group is non-fluorinated, or partially or completely fluorinated. The ionic liquids according to the invention are suitable, for example, as solvents for syntheses, as mobile and/or stationary phases in chromatography, as electrolyte systems for batteries, electrochemical elements, fuel cells and accumulators. Alternative processes according to the invention produce ionic liquids by the reaction of ketene N,N-diacetals or alkylalkylidenephosphoranes or arylalkylidenephosphoranes with acids.
C07D 233/06 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle
C07D 233/54 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07C 211/63 - Composés d'ammonium quaternaire ayant des atomes d'azote quaternisés liés à des atomes de carbone acycliques
The invention relates to a novel arrangement for less expensively and more quickly visualizing a plurality of optical phenomena by means of a minimum of elements of said arrangement. The inventive arrangement can simultaneously be used as a teaching aid and a learning aid while allowing optical phenomena to be visualized for a plurality of students at the same time.
G09B 23/22 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la physique pour l'optique
G09B 19/00 - Enseignement non couvert par d'autres groupes principaux de la présente sous-classe
99.
TRIMERIC, WATER-SOLUBLE AMINOPYRAZOLE COMPOUNDS HAVING AN EFFECT AGAINST NEURODEGENERATIVE DISEASES
The invention relates to trimeric, water-soluble aminopyrazole compounds of formula (I), wherein R1 represents H, a straight-chain or branched alkyl group with up to 10 carbon atoms or an amino acid group or polyamino acid group, and R2 represents an OH, OR3 or NHR3 group in which R3 is a straight-chain or branched alkyl group with 1 to 10 carbon atoms or an amino acid group or polyamino acid group.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
100.
METHOD FOR THE PRODUCTION OF A CHEMICALLY MODIFIED PROTEIN
Disclosed is a method for producing a chemically modified protein, in which an auxiliary protein that carries a reactive, functional group and is composed of an intein fragment and an extein sequence is modified with a group to be introduced into the target protein in a first step, and a target protein that is fused with the intein fragment to be modified and with a complementary intein fragment is reacted in a second step such that the modified extein sequence is combined with the target protein.
brevets
